QTRXHealthcare · Medical DevicesThe 3 Wall Street analysts covering Quanterix Corp. hold a median 12-month price target of $3 — +3.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Quanterix Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (71): Smaller than most of the companies we track.
Momentum (25): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on QTRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +3.3% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | TD Cowen | Maintains | Hold | $3.00 → $3.50 |
| 17 Aug 2026 | Canaccord Genuity | Maintains | Hold | $4.00 → $3.00 |
| 17 Aug 2026 | Canaccord Genuity | Maintains | Hold | — |
| 11 Aug 2026 | TD Cowen | Maintains | Hold | $4.00 → $3.00 |
| 11 Aug 2026 | TD Cowen | Maintains | Hold | — |
| 7 May 2026 | TD Cowen | Maintains | Hold | $7.00 → $4.00 |
| 7 May 2026 | TD Cowen | Maintains | Hold | — |
| 20 Apr 2026 | Canaccord Genuity | Maintains | Hold | — |
| 22 Dec 2025 | Canaccord Genuity | Maintains | Hold | — |
| 11 Aug 2025 | Canaccord Genuity | Downgrade | Hold | — |
| 13 May 2025 | Canaccord Genuity | Maintains | Buy | — |
| 30 Apr 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 25 Mar 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 18 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 13 Nov 2024 | TD Cowen | Maintains | Hold | — |
| 12 Aug 2024 | Scotiabank | Maintains | Sector Outperform | — |
| 9 Aug 2024 | TD Cowen | Maintains | Hold | — |
| 9 July 2024 | Goldman Sachs | Maintains | Buy | — |
| 29 Apr 2024 | Canaccord Genuity | Maintains | Buy | — |
| 4 Mar 2024 | Scotiabank | Maintains | Sector Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
QTRX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Quanterix Corp. returned −41.9% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 70% of US stocks
Cheaper than 81% of US stocks
Cheaper than 70% of US stocks
Higher than 80% of US stocks
Higher than 68% of US stocks
Higher than 47% of US stocks
Higher than 15% of US stocks
Higher than 7% of US stocks
Higher than 22% of US stocks
Higher than 22% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Quanterix Corp. has a market value of $137.4M and an enterprise value of $77.2M.
Revenue in the twelve months to 30 June 2026: $153.2M. The latest quarter grew 34.4% year on year.
Net income over the same four quarters: −$123.1M, a −80.3% net margin.
Diluted earnings per share, trailing twelve months: $−2.63.
Free cash flow in the twelve months to 30 June 2026: −$81.7M.
Trailing P/E: −1.2×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Quanterix Corp. employs 450 people — $341K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Quanterix Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Quanterix announced it will release its third-quarter 2026 financial results before a conference call on November 9, 2026, at 8:30 a.m. ET.
Why it matters — QTRX watchers can note the scheduled date and time for the company's results announcement and discussion.
Quanterix and Innovita announced regulatory approvals from China’s National Medical Products Administration to expand access to Quanterix SIMOA technology and neurology biomarker testing in China. The companies’ commercialization arrangement was initially formed in 2024.
Why it matters — The approvals represent progress in expanding access to Quanterix’s technology and testing through its arrangement with Innovita in the Chinese market.
Quanterix reported progress on its Content Innovation Engine at the European Society for Spatial Biology meeting on September 28-October 1, 2026, updating initiatives originally introduced at the AACR Annual Meeting 2026. The company highlighted its growing leadership in spatial biology content, delivering assays for researchers.
Why it matters — QTRX watchers would care because the company is demonstrating delivery on its spatial biology content innovation commitments, reinforcing its competitive position and growth in that market.
Quanterix Corporation announced inducement grants made on September 15, 2026 under Nasdaq Listing Rule 5635(c)(4) to newly appointed Chief Commercial Officer James Gute, consisting of 260,315 restricted stock units, and to two other employees in connection with the commencement of their employment.
Why it matters — This reporting of equity grants provides transparency to QTRX watchers about executive compensation tied to the hiring of the new Chief Commercial Officer.
Quanterix Corporation announced that Dr. Yuri Fesko has been appointed Chief Medical Officer, where he will provide medical and clinical leadership across the company, working with Diagnostics, Scientific, R&D, Regulatory, and Commercial teams to advance Quanterix's technologies and applications.
Why it matters — A QTRX watcher would care because adding a physician executive to the leadership team signals strengthened medical and clinical expertise across the company's diagnostic and R&D efforts.
The 3 Wall Street analysts covering Quanterix Corp. have a median 12-month price target of $3, with estimates ranging from $3 to $3.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Quanterix Corp., 0 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quanterix Corp. 39 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Quanterix Corp. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (71 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +3.3% from the last close, and Ticker Nerd's factor model ranks Quanterix Corp. 39 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Quanterix Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QTRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3.5 over the next 12 months.
Quanterix Corp. returned -41.9% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Quanterix Corporation is a life sciences tools and diagnostics company that develops ultra-sensitive digital immunoassay platforms for research and clinical applications. Quanterix’s core products and services include the Simoa assay kits, automated analyzers, biomarker detection systems, imaging and analysis platforms, and laboratory services used to measure very low levels of proteins and other biomarkers in blood and related fluids.
The most recent item we track (Business Wire, 28 Oct 2026): "Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026". Quanterix announced it will release its third-quarter 2026 financial results before a conference call on November 9, 2026, at 8:30 a.m. ET.
Quanterix Corporation is a life sciences tools and diagnostics company that develops ultra-sensitive digital immunoassay platforms for research and clinical applications. Quanterix’s core products and services include the Simoa assay kits, automated analyzers, biomarker detection systems, imaging and analysis platforms, and laboratory services used to measure very low levels of proteins and other biomarkers in blood and related fluids. The company supports work across disease research, diagnostics, and drug development, helping laboratories and healthcare organizations generate precise biomarker data for scientific and clinical use. Quanterix serves customers in North America, Europe, the Middle East, Africa, and the Asia Pacific regions, with offerings used by academic researchers, biopharmaceutical companies, and clinical laboratories. Founded in 2007 and headquartered in Billerica, Massachusetts, Quanterix Corporation plays a specialized role in precision biomarker science and advanced diagnostic testing.
CEO Mr. Everett V. Cunningham · 450 employees · United States · https://www.quanterix.com
